Zacks Investment Research·6 days ago
Here's Why Globus Medical (GMED) is a Strong Momentum StockThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Globus Medical, Inc.(GMED)Earnings, Financials & Key Ratios
GMED•NYSE
$78.83
20.1× P/E·Price updated Jul 7, 2026
AboutGlobus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.Show more
- Revenue$2.94B+16.7%
- EBITDA$600M+42.8%
- Net Income$538M+422.3%
- EPS (Diluted)3.92+422.7%
- Gross Margin67.41%+14.4%
- EBITDA Margin20.41%+22.4%
- Operating Margin16.33%+147.8%
- Net Margin18.3%+347.8%
- ROE12.29%+388.0%
GMED Price & Volume
Globus Medical, Inc. (GMED) stock price & volume — 10-year historical chart
Loading chart...
Post-Merger Margin Recovery Drives Scalable Growth
Investment Thesis • Updated 2026Q1
VerdictPositive
Growth:Accelerating
Profitability:Moderate
Financial:Healthy
Cash Flow:Improving
Primary Risk:Merger integration execution risk
Key Thesis Takeaways
- Globus Medical is successfully navigating the integration of the NuVasive portfolio, evidenced by a robust 27.0% year-over-year revenue growth rate in 2026Q1 and a significant recovery in gross margins to 69.2%.
- The company has demonstrated disciplined capital management by aggressively deleveraging, reducing its debt-to-equity ratio from 0.13 in 2024Q4 to 0.02 in 2026Q1.
- Investors should monitor the ongoing $1.4B goodwill concentration and the persistent pressure on SG&A expenses, which remain elevated at $297.8M, as the firm balances market share expansion with long-term profitability targets.
Verdict Logic
the company's successful deleveraging to a 0.02 debt-to-equity ratio and a forward P/E of 18.18 suggest an attractive entry point for investors seeking exposure to a scaling spine-tech leader.
GMED Growth Metrics
Globus Medical, Inc. (GMED) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years18.36%
5 Years30.08%
3 Years42.16%
TTM23.49%
Profit CAGR
10 Years16.91%
5 Years39.37%
3 Years41.42%
TTM216.19%
EPS CAGR
10 Years12.85%
5 Years31.16%
3 Years28.44%
TTM219.4%
Return on Capital
10 Years11.35%
5 Years8.1%
3 Years6.04%
Last Year10.43%
GMED Recent Earnings
Globus Medical, Inc. (GMED) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.12+21.7%
$0.92
Rev
$760M+2.6%
$740M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$1.28+20.8%
$1.06
Rev
$826M+3.1%
$802M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.18+51.1%
$0.78
Rev
$769M+4.7%
$735M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.86+13.2%
$0.76
Rev
$745M+0.4%
$743M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.12vs $0.92+21.7% | $760Mvs $740M+2.6% |
| Q1 2026 | Feb 24, 2026 | $1.28vs $1.06+20.8% | $826Mvs $802M+3.1% |
| Q4 2025 | Nov 6, 2025 | $1.18vs $0.78+51.1% | $769Mvs $735M+4.7% |
| Q3 2025 | Aug 7, 2025 | $0.86vs $0.76+13.2% | $745Mvs $743M+0.4% |
Based on last 12 quarters of dataView full earnings history →
Latest GMED News
Recent stock market news and headlines for Globus Medical, Inc. (GMED)
Zacks Investment Research·Jun 29, 2026
GMED vs. MDT: Which Medical Stock Has More Upside Potential?Globus Medical or Medtronic? See why Globus Medical's stronger growth, innovation and analyst upside may give it the edge despite a richer valuation.
Zacks Investment Research·Jun 26, 2026
Why Globus Medical (GMED) is a Top Value Stock for the Long-TermThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research·Jun 22, 2026
GMED vs. PEN: Which Stock Should Value Investors Buy Now?Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
Zacks Investment Research·Jun 22, 2026
Here's How Macro Trends and Currency Headwind Restrict GMED's GrowthGlobus Medical faces inflation, geopolitical and currency pressures as rising costs and FX losses cloud margin flexibility and international growth.
Peers Comparison
Key metrics vs top competitors for Globus Medical, Inc. (GMED)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $78.83 | $10.63B | 20.11 | 16.65% | 18.3% | 12.29% | — | |
| $313.38 | $120.14B | 37.31 | 11.16% | 13.21% | 15.1% | — | |
| $89.41 | $17.51B | 25.19 | 7.2% | 9.05% | 5.77% | — | |
| $9.38 | $1.42B | -9.77 | 24.95% | -21.07% | -443.09% | — | |
| $0.42 | $58.84M | 13.98 | 14.21% | 1.5% | 3.68% | — | |
| $83.83 | $107.63B | 22.47 | 8.43% | 13.2% | 9.78% | — |
Compare GMED vs Peers
Globus Medical, Inc. (GMED) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GMED SEC Filings & Documents
Globus Medical, Inc. (GMED) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Feb 24, 2026·SEC
10-K Annual Reports
410-Q Quarterly Reports
6Get notified when GMED posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GMED Frequently Asked Questions
Globus Medical, Inc. (GMED) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Globus Medical, Inc.'s revenue?
Globus Medical, Inc. (GMED) reported $3.10B in revenue for fiscal year 2025. This represents a 976% increase from $288.2M in 2010.
How fast is Globus Medical, Inc. growing?
Globus Medical, Inc. (GMED) grew revenue by 16.7% over the past year. This is strong growth.
Is GMED profitable?
Yes, Globus Medical, Inc. (GMED) is profitable, generating $586.7M in net income for fiscal year 2025 (18.3% net margin).
Dividend & Returns
What is GMED's return on equity?
Globus Medical, Inc. (GMED) has a return on equity (ROE) of 12.3%. This is reasonable for most industries.
What is Globus Medical, Inc.'s free cash flow?
Globus Medical, Inc. (GMED) generated $605.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.